Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$4.19 - $6.23 $32,426 - $48,213
-7,739 Reduced 34.38%
14,773 $67,000
Q1 2024

Apr 29, 2024

SELL
$5.69 - $8.08 $149,322 - $212,043
-26,243 Reduced 53.83%
22,512 $135,000
Q4 2023

Feb 07, 2024

BUY
$3.77 - $8.39 $27,377 - $60,928
7,262 Added 17.5%
48,755 $389,000
Q3 2023

Nov 02, 2023

BUY
$5.2 - $8.77 $36,259 - $61,153
6,973 Added 20.2%
41,493 $268,000
Q2 2023

Aug 07, 2023

BUY
$5.86 - $7.93 $34,286 - $46,398
5,851 Added 20.41%
34,520 $207,000
Q1 2023

May 09, 2023

SELL
$5.85 - $9.84 $21,317 - $35,856
-3,644 Reduced 11.28%
28,669 $177,000
Q4 2022

Feb 09, 2023

BUY
$6.88 - $9.55 $94,758 - $131,532
13,773 Added 74.29%
32,313 $298,000
Q3 2022

Nov 09, 2022

SELL
$8.19 - $13.2 $2,579 - $4,158
-315 Reduced 1.67%
18,540 $176,000
Q2 2022

Aug 10, 2022

BUY
$7.65 - $14.24 $62,431 - $116,212
8,161 Added 76.31%
18,855 $192,000
Q1 2022

May 09, 2022

SELL
$13.02 - $20.78 $116,138 - $185,357
-8,920 Reduced 45.48%
10,694 $152,000
Q4 2021

Feb 09, 2022

SELL
$19.35 - $25.54 $163,507 - $215,813
-8,450 Reduced 30.11%
19,614 $405,000
Q3 2021

Nov 09, 2021

BUY
$21.65 - $39.49 $209,810 - $382,697
9,691 Added 52.75%
28,064 $641,000
Q2 2021

Aug 10, 2021

BUY
$15.5 - $22.48 $11,811 - $17,129
762 Added 4.33%
18,373 $382,000
Q1 2021

May 10, 2021

SELL
$14.84 - $22.23 $159,010 - $238,194
-10,715 Reduced 37.83%
17,611 $355,000
Q4 2020

Feb 08, 2021

BUY
$9.4 - $16.7 $112,865 - $200,516
12,007 Added 73.58%
28,326 $429,000
Q3 2020

Nov 06, 2020

SELL
$10.54 - $24.96 $8,347 - $19,768
-792 Reduced 4.63%
16,319 $172,000
Q2 2020

Aug 05, 2020

SELL
$21.87 - $33.11 $183,073 - $277,163
-8,371 Reduced 32.85%
17,111 $418,000
Q1 2020

May 12, 2020

BUY
$16.25 - $35.28 $8,742 - $18,980
538 Added 2.16%
25,482 $615,000
Q4 2019

Feb 05, 2020

BUY
$14.17 - $20.3 $353,456 - $506,363
24,944 New
24,944 $430,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $159M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.